EAM Investors’s Ligand Pharmaceuticals LGND Stock Holding History

EAM Investors’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.16M	Buy	+19,498	New	+$4.59M	0.55%	61
2026 Q1	–	Sell	-21,092	Closed	-$3.99M	–	336
2025 Q4	$3.99M	Sell	21,092 -9,083	-30%	-$1.75M	0.44%	117
2025 Q3	$5.26M	Buy	+30,175	New	+$4.49M	0.6%	51
2018 Q4	–	Sell	-22,442	Closed	-$3.84M	–	285
2018 Q3	$3.84M	Sell	22,442 -1,709	-7%	-$258K	0.57%	38
2018 Q2	$3.12M	Sell	24,151 -9,539	-28%	-$1.06M	0.49%	82
2018 Q1	$3.47M	Buy	+33,690	New	+$3.33M	0.58%	43
2015 Q4	–	Sell	-35,426	Closed	-$1.89M	–	339
2015 Q3	$1.89M	Sell	35,426 -8,233	-19%	-$500K	0.3%	154
2015 Q2	$2.75M	Sell	43,659 -29,064	-40%	-$1.59M	0.32%	148
2015 Q1	$3.5M	Buy	+72,723	New	+$2.79M	0.4%	79
2014 Q3	–	Sell	-27,674	Closed	-$1.07M	–	338
2014 Q2	$1.07M	Sell	27,674 -13,449	-33%	-$546K	0.2%	282
2014 Q1	$1.73M	Sell	41,123 -5,944	-13%	-$248K	0.31%	118
2013 Q4	$1.54M	Sell	47,067 -56	-0.1%	-$1.82K	0.28%	138
2013 Q3	$1.27M	Sell	47,123 -79,980	-63%	-$2.25M	0.25%	156
2013 Q2	$2.97M	Buy	+127,103	New	+$2.29M	0.64%	21

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EAM Investors's LGND Position: Q2 2026 in Review

EAM Investors opened a new position in Ligand Pharmaceuticals (LGND) in Q2 2026: 19,498 shares worth $6.16M. The stake represents 0.55% of the portfolio and ranks #61 among its holdings. This is a return to the name: EAM Investors previously reported a position in LGND as recently as Q4 2025.

EAM Investors first reported a position in LGND in Q2 2013 and has held it in 14 quarters since. 417 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

EAM Investors held 19,498 shares of Ligand Pharmaceuticals worth $6.16M as of Q2 2026.
Ligand Pharmaceuticals was a new EAM Investors position in Q2 2026.
Ligand Pharmaceuticals made up 0.55% of EAM Investors's portfolio in Q2 2026, its #61 holding.
EAM Investors first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 14 quarters since.
417 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on EAM Investors's 13F filing for Q2 2026, filed 13 Aug 2026.